PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1753424
PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1753424
Global Cell and Gene Supply Chain Services Market to Reach US$2.2 Billion by 2030
The global market for Cell and Gene Supply Chain Services estimated at US$1.4 Billion in the year 2024, is expected to reach US$2.2 Billion by 2030, growing at a CAGR of 7.5% over the analysis period 2024-2030. Presence On Cloud Technology, one of the segments analyzed in the report, is expected to record a 6.1% CAGR and reach US$1.4 Billion by the end of the analysis period. Growth in the Presence ln-Premises Technology segment is estimated at 10.1% CAGR over the analysis period.
The U.S. Market is Estimated at US$382.5 Million While China is Forecast to Grow at 11.4% CAGR
The Cell and Gene Supply Chain Services market in the U.S. is estimated at US$382.5 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$451.4 Million by the year 2030 trailing a CAGR of 11.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.8% and 7.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.9% CAGR.
Global Cell and Gene Supply Chain Services Market - Key Trends & Drivers Summarized
What’s Fueling the Revolution in Cell and Gene Therapy Logistics?
The cell and gene supply chain services market is undergoing a dynamic transformation as cell and gene therapies (CGTs) transition from niche experimental treatments to mainstream clinical applications. These therapies demand highly specialized logistics due to their sensitivity to temperature, time, and contamination. As the number of approved cell and gene therapies continues to rise globally, the need for tailored supply chain services is intensifying. This includes cold chain logistics, real-time tracking, cryopreservation, and secure, timely transportation between manufacturing sites and treatment centers. Traditional pharmaceutical logistics infrastructures are ill-suited to handle these complexities, prompting an industry-wide shift toward specialized providers.
The rising number of clinical trials for CGTs-especially autologous therapies that require patient-specific manufacturing-has heightened the need for precise, integrated supply chain models. These services must not only ensure product integrity but also maintain chain-of-identity and chain-of-custody throughout the process. The logistical challenges become even more intricate with international trials, where regulatory standards, time zone management, and customs requirements can introduce critical risks. This is creating a premium on supply chain agility and compliance expertise, fueling demand for vendors offering end-to-end solutions.
How Are Technological Advances Reshaping the Supply Chain Landscape?
Cutting-edge technologies are redefining how cell and gene therapies are transported, tracked, and monitored. Real-time GPS and IoT-enabled monitoring systems are becoming industry standards, allowing continuous surveillance of temperature, location, and other critical parameters. Such advancements are vital for maintaining the integrity of living therapies, which can degrade or become nonviable if environmental conditions deviate from their required ranges. Automation, robotics, and AI are also streamlining warehouse operations and predictive maintenance within cold storage environments, reducing human error and operational inefficiencies.
In addition, the use of blockchain for secure tracking is gaining traction, ensuring an immutable digital ledger of the product journey. This innovation supports compliance with regulatory demands for traceability, especially in Europe and North America. Another game-changing development is the emergence of digital twins-virtual models that simulate supply chain logistics under various scenarios to optimize outcomes and preempt disruptions. These technologies are empowering stakeholders to enhance visibility, mitigate risks, and improve on-time delivery of life-saving treatments, positioning tech-driven firms at the forefront of the market.
Why Are Strategic Collaborations and Regulatory Compliance Critical?
The intricate and high-stakes nature of CGT logistics necessitates close collaboration across multiple stakeholders, including biopharma companies, logistics providers, hospitals, and regulators. Partnerships between therapy developers and specialized logistics firms are becoming more frequent, aiming to streamline operations, align timelines, and meet strict quality standards. Pharmaceutical companies are increasingly outsourcing their logistics to third-party vendors with dedicated CGT expertise rather than building internal capabilities from scratch. These partnerships are often structured as long-term alliances to ensure stability and shared investment in innovation.
Regulatory compliance remains a critical focus, especially as authorities tighten guidelines around temperature control, product traceability, and documentation. Agencies such as the FDA, EMA, and PMDA are reinforcing Good Distribution Practice (GDP) regulations, and companies that can demonstrate full adherence are gaining a competitive edge. Moreover, regulatory harmonization efforts between regions are simplifying cross-border transport, reducing delays, and expanding access to emerging markets. The synergy of strategic alliances and robust compliance infrastructure is proving essential in navigating the unique challenges of this supply chain sector.
What Are the Core Drivers Behind Market Acceleration?
The growth in the cell and gene supply chain services market is driven by several factors. The surge in cell and gene therapy development, with hundreds of products in clinical pipelines globally, is increasing the demand for customized, high-integrity logistics. Advances in biotechnology and the shift toward personalized medicine are emphasizing the need for precise, patient-centric transport solutions. The complexity of handling living therapies is also necessitating expanded capabilities in cryogenic storage, temperature-controlled packaging, and last-mile delivery. Additionally, the rise in regulatory scrutiny and the need for digital traceability systems are prompting investments in tech-enabled, compliant supply chain networks. Evolving patient expectations and the globalization of CGT clinical trials are further fueling the requirement for agile, globally harmonized logistics platforms. These converging factors are collectively propelling the market forward, making it one of the fastest-growing niches within healthcare logistics.
SCOPE OF STUDY:
The report analyzes the Cell and Gene Supply Chain Services market in terms of units by the following Segments, and Geographic Regions/Countries:
Segments:
Technology (Presence On Cloud Technology, Presence ln-Premises Technology); End-Use (Biobank / Cell-Bank End-Use, Hospitals End-Use, Research Institutes End-Use, Cell Therapy Labs End-Use, Other End-Uses); Application (Ordering & Scheduling Applications, Sample Collection Applications, Logistics Applications, Post Treatment Follow-Up Application)
Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.
Select Competitors (Total 34 Featured) -
AI INTEGRATIONS
We're transforming market and competitive intelligence with validated expert content and AI tools.
Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.
TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.